Navigation Links
Vermillion Reports Fourth Quarter and Full Year 2011 Results
Date:3/27/2012


Liolios Group, Inc.
Ron Both
Tel 949-574-3860
info@liolios.com Vermillion, Inc.Consolidated Balance Sheets(Amounts in Thousands, Except Share and Par Value Amounts)

(Unaudited)December 31, 20112010AssetsCurrent assets:Cash and cash equivalents

$
22,477$
22,914Accounts receivable

99136Prepaid expenses and other current assets

317779Total current assets

22,89323,829Property and equipment, net

216194Other assets

212Total assets

$
23,111$
24,035Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable

$
,331$
998Accrued liabilities

2,5923,056Short-term debt

7,000-Convertible senior notes

-5,000Deferred revenue

5531,049Total current liabilities

11,47610,103Non-current liabilities:Long-term debt

-7,000Warrant liability

-378Long-term deferred revenue

1,2241,679Other liabilities

52259Total liabilities

12,75219,419Commitments and contingenciesStockholders' equity:Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at December 31, 2011 and 2010

--Common stock, $0.001 par value, 150,000,000 shares authorized; 14,900,831 and 10,657,564 shares issued and outstanding at December 31, 2011 and 2010, respectively

1511Additional paid-in capital

326,796303,270Accumulated deficit

(316,299)(298,509)Accumulated other comprehensive loss

(153)(156)Total stockholders' equity

10,3594,616Total liabilities and stockholders' equity

$
23,111$
24,035Vermillion, Inc.Consolidated Statements of Operations(Amounts in Thousands, Except Share and Per Share Amounts)

(Unaudited)Three months ended December 31, Year Ended December 31, 2011201020112010Revenue:Product

$
755$
49$
,469$
308License

113196454867Total revenue

868345
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
3. Vermillion Reports Results for the Second Quarter 2011
4. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
5. Vermillion Announces Joining Russell Microcap® Index
6. Vermillion Announces Notice of Allowance for Alzheimer Patent
7. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
8. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
9. Stephens Initiates Coverage on Vermillion
10. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
11. Vermillion Announces Issuance of European Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... , , , ALBANY, Ore., ... financial results for the first quarter of fiscal 2010, which ended ... a 5% decrease compared to revenue of $4.9 million in the ... quarter was $1.0 million, compared to operating income of $314,000 for ...
... Md., Aug. 6 GenVec, Inc. (Nasdaq: GNVC ) today ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ... net loss of $4.8 million ($0.05 per share) for the three months ... ($0.08 per share) in the comparable quarter of 2008. For the six ...
... 6 Novavax, Inc. (Nasdaq: NVAX ) announced ... Chief Financial Officer and treasurer. Mr. Driscoll will report ... , , Previously Mr. Driscoll served as ... Genelabs Technologies, Inc. Prior to his position at Genelabs, ...
Cached Biology Technology:Synthetech Reports First Quarter Fiscal 2010 Results 2Synthetech Reports First Quarter Fiscal 2010 Results 3Synthetech Reports First Quarter Fiscal 2010 Results 4Synthetech Reports First Quarter Fiscal 2010 Results 5Synthetech Reports First Quarter Fiscal 2010 Results 6GenVec Reports Second Quarter 2009 Financial Results 2GenVec Reports Second Quarter 2009 Financial Results 3GenVec Reports Second Quarter 2009 Financial Results 4GenVec Reports Second Quarter 2009 Financial Results 5GenVec Reports Second Quarter 2009 Financial Results 6GenVec Reports Second Quarter 2009 Financial Results 7Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer 2
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... consider giving thanks for the bacteria-busting ability of cranberry ... beverage holds important clues for preventing cavities. , ... D.D.S., Ph.D., at the University of Rochester Medical Center ... juice a powerful weapon against bladder infections also hold ...
... : It makes me sad when an article that should ... webpage of the student's group in the iGEM competition , ... for their bacterial 'camera'. , Using Petri dishes full ... at The University of Texas at Austin and UCSF successfully ...
... College of Medicine and the German Cancer Research Institute ... regions of a cell--a process crucial for the cellular ... metastasis. Their study appears in the November 24 issue ... Singer and Dr Stefan Huettelmaier, the research team focused ...
Cached Biology News:Give thanks for the cranberry, say dental researchers 2Give thanks for the cranberry, say dental researchers 3Student scientists create living bacterial photographs 2Student scientists create living bacterial photographs 3Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell 2
Anti Autotaxin /ENPP2 , - (Rabbit)...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Biology Products: